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ABSTRACT
Musculoskeletal tissue engineering involves the creation of multiple tissue types
that interact together to perform a particular function related to motion and maintaining
the body's frame. In order to create a fully functional musculoskeletal system, a concrete
method for the creation of the different tissue types must first be completed. Of the
different tissue components related to the function of a musculoskeletal system, these
studies deal with preconditioning circumstances of stem cells that will differentiate into
cartilage and bone. These studies also deal with methods for the creation of functional
bone and cartilage to be combined for the creation of a musculoskeletal system. The idea
of ischemic preconditioning, a solution for the improvement of ischemic cerebral and
cardiovascular tissues, was adapted in this study to show that it eases the transition of
cells implanted into an injury site to have increased engraftment and survival compared
to current methods. It was also determined that HIFs are vital to this increased survival
of stem cells in a toxic microenvironment of an injury site. That information translated to
the second study dealing with HIF-2's involvement in the onset of hypertrophy. The
contributions of this study show that the use of a HIF-2 inhibitor on ADSCs during
chondrogenic and hypertrophic differentiation allows for increased survival and as a
result increased collagen type II production. Overall, these two studies added
information relating to how stem cells could be prepared for the creation of a
musculoskeletal system for implantation into defect systems.
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CHAPTER 1
INTRODUCTION
Review of Musculoskeletal Tissue Engineering: Bone and Cartilage Engineering
1.1 MUSCULOSKELETAL TISSUE ENGINEERING
Tissue engineering is known as a science for the design and creation of tissue that
can be used to restore impaired organs and systems that have been damaged or lost due to
disease or trauma. 1,2 Tissue engineering is a complex process that is composed of many
different components, each of different importance.3 It can be stated that the main
components of tissue engineering are cells, scaffolds, biological factors/signals, and
preconditioning, through culture conditions or biomechanical loading.2,4 All of these
factors are related to the tissue type being regenerated only by the consideration that stem
cells are the optimal cell choice for musculoskeletal tissue formation and the fact that
they are all taken into account when performing tissue engineering for a specific tissue.
Each component tends to have an optimal choice depending on the tissue being
regenerated.3,5 These components and their relationships are portrayed in figure 1.1. In
the current state of tissue engineering, more specifically musculoskeletal tissue
engineering, the focus of studies have shifted to tissue function because studies have
shown the ability to produce adequate tissue formation, but without the expression of
proper properties.
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Figure 1.1: Diagram showing the general components encompassing a viable tissue engineered implant and the relationships between
them.

Musculoskeletal tissues are interesting in how they integrate and interact with one
another to provide a desired function in the body. For instance, cartilage and skeletal
muscle both interact with bone to give different functions, cartilage for frictionless
movement and support, while the muscle provides the actual power for the desired
motion. Areas where the muscle or tendon insert are usually attained through the use of
an interface composed of a specialized tissue called fibrocartilage.

As seen in this

example, engineering of musculoskeletal tissue entails a variety of different tissue types
that must integrate with one another to create a fully functional musculoskeletal system.
Bone, cartilage, ligaments, muscles and tendons are all different components and tissues
that make up a musculoskeletal system. It is interesting to note that bone is a type of
tissue which is considered to have one of the highest potentials for regeneration of any
tissue in the body, while cartilage on the other hand is one of the most difficult tissues to
regenerate in the body.2 An explanation for this stems from the concept that highly
vascularized tissues will have a greater ability for regeneration due to higher availability
of nutrients, while tissues of less vascularization will regenerate slower or not at all
because of lack of nutrients. This could help to explain the speed at which bone and
cartilage regenerate. Bone is a tissue that is highly vascularized from its initial formation
and receives nutrients constantly and proper concentrations for regeneration. Cartilage
on the other hand, is known to be an avascular tissue, therefore it does not have nutrients
as readily available to help its regeneration.

Of the tissues that make up a

musculoskeletal system, bone and cartilage will be focused on during the rest of this
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chapter to create an understanding of these two tissues to support the studies that were
completed.

1.2 TISSUE ENGINEERING BONE
Bone is a tissue in the body that has multiple functions in the body, such as
providing support, protecting vital organs, and maintaining the body's frame. If there is
an issue with the bone due to disease or trauma there is a need to repair the tissue to
restore it to its full functionality. Current tissue engineering of bone tissue is aimed at
repairing bone problems related to birth defects or critical-size bone defects (CSDs).
CSDs are a consequence of a multitude of different causes, such as tumors, trauma, or
infection. When bone encounters one of these issues the result is considered a CSD only
when the disease or trauma has left the bone in a state where it cannot perform self repair
or regeneration. In eyes of current tissue engineers, a practical way of repairing CSDs is
through the implantation of scaffolds seeded with cells to accelerate the formation and
repair of bone.6–9 Vasculature is an important physiological factor in tissue, no matter the
extent that the tissue is vascularized. At the site of a CSD there is a great loss of
vasculature because of the disease or injury. It has been reported that at a CSD site the O2
concentration can be reduced to levels between 0% and 3%.10–12 Levels of O2 in this
range are considered to be hypoxic, [O2]<5%.

It is known that hypoxia has a

considerable influence on cell behavior because O2 has multiple affects at different
concentrations.13–15
The ultimate goal of tissue engineered bone is a vascularized bone in the subject
that serves all the functions of native bone. When engineering new bone there are
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multiple choices that must be made: in vivo or in vitro, cell type, vascularization before or
after implantation, among many others. Ideally, a completely formed and vascularized
bone would be created in vitro then implanted and integrated to be fully functional, but
that is a difficult goal to reach. It is much more realistic to form the bone in vivo where
the body would undergo vascularization in the bone as it would normally do for any
tissue. When going about the design to engineer bone in the body the cell type is a very
vital factor due to limitations on the capabilities of certain types of cells. Stem cells have
shown to have promising results in the tissue engineering field, including their use for
tissue engineering bone, because of their increased capacity of differentiation into
different tissues and other cellular phenotypes. While many studies have employed bonemarrow derived mesenchymal stem cells, adipose-derived mesenchymal stem cells
(ADSCs) have shown the possibility of being a better source for tissue engineering
because they are easier to harvest.16–18 It is important to note that through the use of stem
cells for tissue engineering, there is a requirement for the cells to differentiate at some
point into the cells of the specific desired tissue type. Most literature on osteogenesis
states that hypoxia has a very detrimental role in osteogenesis, if not completely
inhibiting it, while others have shown the opposite effect on osteogenesis. 19–26 There are
various explanations for differing results. These explanations range from cell source,
because older subject's stem cells portray reduced phenotypes and differentiation
capabilities, to the exposure time or the specific O2 concentration used.27
Current hurdles in tissue engineering of any kind, more prominent in bone, are the
engraftment and survival of implanted tissue. The current method for bone tissue
engineering studies is culture of the cells at atmospheric conditions with culture or
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differentiation medium based on the study being performed. When the desired tissue has
formed in vitro the cells are transplanted into the animal subject of interest and after some
period of time the viability of the implanted tissue is examined. The result of this type of
study is typically poor engraftment and low viability. Typical explanations for this relate
to the drastic change from the exposure of atmospheric O2 concentration (20% O2) during
culture to the hypoxic O2 levels of the injured tissue which is typically around 1% O2 or
less.

This drastic change results ultimately numerous effects such as inflammatory

response and ischemia-reperfusion (IR), but the main cause of low survival and
engraftment is apoptosis.28–34 As a result of this effect, there is a need for the formulation
of approaches to improve cell survival to help increase engraftment and capabilities for
their differentiation.
One such strategy has been proposed that would result in numerous responses
including activation of different survival signaling pathways for protection in the toxic
environment of an injury. Ischemic preconditioning (IPC) is the proposed method and
has been studied for transplanting cells into different tissues such as infracted
myocardium and ischemic brain and limb tissue.35–48 IPC has shown a cytoprotective
effect of stem cells through the upregulation of VEGF, anti-apoptotic proteins Bcl-2, Bclxl, and erythropoietin (EPO), which are all considered to be survival proteins.24,40,48–50
While those proteins are considered anti-apoptotic, there are also proteins that have an
agonistic effect on the apoptotic pathway called pro-apoptotic proteins. Some of the
proteins viewed more frequently in literature are active caspase-3and more importantly
the pro-apoptotic protein involved with Bcl-2 called Bax. The analysis of pro-apoptotic
proteins has been used as a way to determine how much apoptosis occurs. Therefore, Bax

6

levels are used to determine conditional effects on survival. As previously stated, it has
been well studied that hypoxia has adverse effects on osteogenic capabilities.19,21,25,51 An
injury site is a hypoxic environment, therefore no matter what type of implant is created,
it will have to be implanted into a hypoxic environment.10,11,52 An important question
posed through this statement is prior to transplantation whether stem cells should be
cultured under atmospheric or ischemic conditions similar to those experienced at the
CSD site.

1.3 TISSUE ENGINEERING CARTILAGE
Cartilage serves different purposes related to its location in the body and the type
of cartilage it is composed of. Cartilage serves to create smooth surfaces for frictionless
motion to reduce damage, provide support and rigidity, and also to define and maintain
shape. Currently 70% of Americans over the age of 65, approximately 12.4 million, are
affected by osteoarthritis (OA), a cartilage disease that changes the ability of cartilage to
complete the roles that it serves stated above.53,54 Looking to the future, the baby boomer
population is approaching this age and that means a dramatic increase in the number of
joint injury cases that will need to be repaired.55
The three types of cartilage are elastic, fibrocartilage, and hyaline cartilage.
Articular cartilage, found in thin layers between bones, creates a relatively frictionless
surface for the ends of the two long bones to move ensuring no damage occurs. Synovial
fluid present in the joints also facilitates this process. Another important purpose of the
synovial fluid is to provide chondrocytes with nutrients, even though it is a limited
reservoir. Chondrocytes are the resident cell type of cartilage, but they are so sparsely
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found in the tissue that cartilage is considered to be acellular. Along that same note,
cartilage is also considered to be avascular because it lacks a true blood supply which
feeds the chondrocytes. As a result cartilage tissue shows a low capacity for quick repair,
if repair at all.56 Another result of a limited nutrient supply that does not come directly
from the blood, the physiological oxygen concentration found in cartilage is significantly
lower than found in other tissues of the body. Physiological O2 concentrations range from
approximately 1-7%. Cartilage is found on the lower end of that range around 1% or 2%,
an environment considered to be hypoxic.
Majority of cartilage tissue engineering studies focuses on cartilage defects of
the articular layer between bones, i.e. dealing with hyaline cartilage.55 Current attempts
to engineering articular cartilage have met numerous drawbacks. One result of tissue
engineered cartilage is a tissue expressing markers of fibrocartilage. Fibrocartilage also
shows up as a repair mechanism for injured cartilage, but it has been shown that the
mechanical properties, load-bearing capabilities and ability to handle stress, of this
cartilage is not sufficient to be used to replace damaged hyaline cartilage. This becomes a
problem in development of engineered cartilage because it results in the development of
larger problems that could form chronic issues if not properly repaired.4,53,56–58 As far as
marker expression, the main difference between hyaline cartilage and fibrocartilage is
that fibrocartilage has collagen type I with collagen type II, whereas hyaline cartilage
only expresses collagen type II. This explains why there is a reduction in mechanical
properties of fibrocartilage compared to hyaline. Chondrocytes in any type of cartilage
are responsible for production and maintenance of the ECM. The composition and
amount of each ECM components depends on the cartilage type and site in the body.
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ECM of hyaline cartilage usually consists of collagen, proteoglycans, and other matrix
proteins. Collagen type II is the prominent type of collagen in hyaline cartilage for its
shock absorbing capabilities and it makes up a good portion of the ECM along with
proteoglycans, which have glycosaminoglycans (GAGs) attached.59
Current treatment options for cartilage defects are limited, but also not complete
repairs of the defect in the current state of cartilage repair. There are a number of
possible options that can be explored to repair cartilage damage. Some of these treatment
strategies are autologous chondrocyte implantation (ACI), fairly well known;
mosaicplasty, and microfracture. The success of these treatments has been shown to
vary, but on a long-term scale they are considered to be unsatisfactory because they do
not fully solve the problem or they just delay the further onset of the disease.60–65 The
current issue with treatment for repairing damaged cartilage are the components of native
cartilage and the ability to maintain sufficient mechanical capabilities that have been lost
in regenerated tissue.66 Therefore, the new cartilage is insufficient and will undergo
degradation as a result of the high loads and stress encountered. ACI is more frequently
used for cartilage repair, but this treatment does have some flaws that could be solved by
a procedure for creating of a functional cartilage implant that can maintain its properties.
ACI hurdles one of the largest debates in these types of surgeries, cell source. The reason
cell source is very important here is the same reason seen in any other surgery which uses
an implant. The implant must be biocompatible and not illicit an immune response. In
ACI, cells are harvested from a non-load-bearing portion of the cartilage and then
expanded ex vivo until they have reached a volume large enough for re-implantation. By
using the patient's own cells they are able to disregard the issues of immuno-rejection one
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would possibly face with implanting primary chondrocytes or stem cells from another
source. Although they do not trigger an immune response, they include an extra surgery
in order to harvest the cartilage from the patient and then a final surgery to implant them
into the patient. This increases the expense of the procedure and if a method for the
creation of viable cartilage implants were created it would have the possibility of
reducing the cost of the procedure, let alone result in a reduction in the number of times
the patient would have to go under the knife. There have been multiple comparative
studies of the different defect treatments which have yielded good comparisons. ACI was
found to be more beneficial than mosaicplasty when examined after one year via
arthroscopy. Two year post-surgery assessment yielded little difference between the two
treatments based on a scoring system used for assessment. Also at two years after the
surgery, the tissue composition found in the ACI treated cartilage resulted in mainly
fibrocartilage or a mix of fibrocartilage with hyaline cartilage. Mosaicplasty on the other
hand, showed qualities similar to that of the defective tissue found prior to surgery.65,67–69
As multiple studies have been performed to understand the true effectiveness of the
surgeries it has been shown that ACI has the possibility of having both satisfactory and
unsatisfactory results, but one thing is known, that the issue is not being completely
fixed. The biggest factor seen in this range is the different complications or conditions of
the trial subjects. If a patient has already had surgery they were not used. Table 1.1
shows a comparison of some important observations of the three different cartilage defect
treatment.
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Table 1.1: Comparison of the treatment solutions for cartilage defects.

Regenerated Tissue
Composition
Further
Complications/Surgeries
Post-Surgery Function
Rating (Cincinnati
Method)
One Year Post-Surgery
Arthroscopy
Cost

ACI
Fibrocartilage
and Hyaline mix
Yes

Surgery Type
Mosaicplasty
Similar to original
defective tissue
Yes

88%

69%

Not determined

82% good
repairs
~$25,000

34%

Not determined

~18,000

>$7,000

Microfracture
Not determined
Yes

Although ACI is the most expensive surgery, it has been remarked that ACI is
most cost-beneficial of the three surgeries. One drawback with ACI, and possibly the
other treatments, is that the possibility for further surgeries down the road to shave off
hypertrophic cartilage around the defect area is a greater possibility. It is also interesting
to note that these treatments tend to not be performed on defect areas showing signs of
OA.68 This makes the need for a suitable tissue engineered cartilage implant even more
important because it would have the ability to solve the defects currently treated with
ACI, mosaicplasty, or microfracture, while also treating those that are unable to be
repaired through those surgeries; i.e. osteoarthritic tissue.
Currently, the field lacks a set protocol for creating cartilage that has been
accepted or has FDA approval. There are multiple factors which go into producing an
implantable tissue construct, beyond the ideologies that the implant must be
biocompatible, preserve function, have a stable composition, and maintain itself while
integrating with surrounding tissue. Four general factors which make an implant perform
and satisfy the requirements are portrayed in figure 1.1 and are as follows: biological
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factors, cells, biomechanical forces and scaffolds. Biological factors are chemicals, any
compound that has an effect on cellular behavior, whether their production is induced or
they are supplemental. Typically for tissue engineering biological factors either inhibit
tissue from forming a nonfunctional phenotype or are used to drive a cell toward the
desired phenotype. Biological factors can also be used to simulate a physiological
environment in vitro which is unattainable because it is not produced by the tissue. For
example, hypoxia-inducible factor 1α (HIF-1α) is a direct regulator of vascular
endothelial growth factor (VEGF), if HIF-1α were knocked-out or inhibited to stop
specifically the production of another gene, there would be a need for a VEGF
supplement to maintain the physiological levels. The next component of cartilage tissue
engineering, scaffolds, is a constituent which has a lot of variability based on its
composition. The designer has the option to pick a variety of different materials to create
the scaffold which will be seeded with cells to be implanted into the injury site. Ideally
this material will be biocompatible at least if not also biodegradable, which does reduce
the overall variety of choices to some extent. Physiologically, cartilage in the human
knee undergoes thousands of loading/unloading cycles per day. These are biomechanical
forces which can be utilized during the creation of the cartilage implant to prepare it for
the defect site. Therefore, biomechanical preconditioning will prepare the construct to
withstand the same types of forces it will encounter at the injured joint. Biomechanical
forces are also responsible for regulating gene expression which can be advantageous if
they are desired. For example, studies have shown that specific mechanical stimuli will
cause a down regulation of proteins associated with the chondrocyte phenotype, i.e.
collagen II and Sox9.70 Biomechanical force studies could show that forces supplied in
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different forms leads to production of specific genes for survival, such as the antiapoptotic factors, or the production of the proper extracellular matrix, ECM, components,
like collagen type II, that would give the engineered tissues properties visible in native
tissue. The final components for creating a cartilage implant are the cells used for its
creation. There are a number of sub-components determining what this category is. The
cell type must first be determined so that the source of these cells can then be decided.
For example, if the cell type used is primary chondrocytes, which have a higher immune
response if used between different subjects, then the ideal choice of source would be
from the person in whom the engineered construct will be implanted. Selecting stem
cells opens up a larger box because then the type of stem cell is also to be questioned,
whether it could be mesenchymal stem cells, induced pluripotent stem cells (iPS), or
embryonic stem cells. Taking into consideration how all of these components interact is
important because they affect each other. More details on specifics of cell types will
follow later.
In a way, there is a current tissue engineering method for cartilage repair used to
treat defects. ACI can be viewed as such because cells are harvested from the patient and
expanded to a larger population before being implanted at the defect site. Although, no
other alteration is done to harvest cells they are expanded for re-implantation. This is also
known as an ex vivo process. There have been other attempts to solve the unsatisfying
results, but have run into a few issues which have restricted advances in the field. The
biggest disadvantage is the onset of hypertrophy in cells of in vitro, in vivo, or ex vivo
studies, which seems to be inevitable through the current culture systems.4 Another issue
is visible during the expansion phase of the ex vivo repair system (ACI), where the cells
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tend to dedifferentiate. The cells will undergo re-differentiation during integration at the
defect site, or as part of the progression towards physiological cartilage in experimental
studies. This re-differentiation tends to produce cells which portray a phenotype that is
deficient in the mechanical properties of cartilage compared to the target tissue deeming
it unusable. The problem with the re-differentiated tissue is that it secretes a matrix
shown closer in relation to either that of fibrocartilage or of hypertrophic cartilage.
Hypertrophic cartilage is characterized by the swelling of the cells, commonly seen in the
development and formation of long bones in a process called endochondral ossification,
and the production of collagen type X, alkaline phosphatase (ALP), or other secreted
bone factors.71–81 This supports why ACI tissue is composed of fibrocartilage-like
components or possibly some hypertrophic cartilage. Therefore, it is a simple statement
to say that the optimal cartilage implant would be one that encompasses all of the
properties of the physiological cartilage; its load-bearing capabilities, ability to maintain
homeostasis, and exhibits the same ECM components, while integrating into the healthy
tissue surrounding the defect area. This has proved to be a much harder task as there are
many variables that make up this healthy tissue.
Chondrocyte differentiation and culture is a well-studied topic, but there is still
more that must be studied to determine a concrete method, to maintain the chondrocytes
for implantation and integration at the defect site, that will be more successful compared
to the current cartilage repair strategies. When creating anything there is a step which
must be done before starting anything else and that is a very thorough analysis of the
topic of creation. This analysis, in the case of cartilage, would start with a
characterization of chondrocytes and their differentiation process along with a
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characterization of what is not desired, hypertrophy. The current status of research on
chondrocytes has yielded results revealing a lot about the cell type, but as all knowledge
goes, discovery of one thing just leads to a new question. It has been well documented
that Sox9 is important in chondrogenesis and chondrocytes, so important that many refer
to this gene as the master regulator gene for chondrogenesis. It has been shown that this
gene is required for early chondrogenesis, but further studies are required to determine
what else it contributes to in order to truly understand it.82 It is also interesting to note
that Dy and colleagues also showed direct contribution with Mef2 in the activation of
collagen X, the main collagen produced in hypertrophic chondrocytes. They also saw the
need for growth plate chondrocytes to have Sox9, which could mean Sox9 also have
some contribution to hypertrophy, but more studies are needed to clear up this
unanswered question. A study performed on maturation and terminal differentiation of
chick chondrocytes showed that as time passed, HIF-2α levels were elevated above
normal levels. This led to speculation that HIF-2 has a very crucial role in chondrocyte
maturation and possibly in their terminal differentiation.73,83 Other known proteins
produced by chondrocytes are aggrecan, GAGs, collagen II, among others. As far as
chondrocytes go, studies differ in results implicating HIFs as regulating chondrogenesis
or hypertrophy; therefore, more in depth studies are required to truly determine their
specific roles in each process to move the field forward.
Understanding different roles that hypertrophy plays in the body can also help
draw conclusions to be used in formulating a method for engineering cartilage.
Hypertrophy has a crucial role in limb development; as long bones grow, cartilage
undergoes hypertrophy to make room for osteocytes to invade and create bone. Multiple
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studies have examined gene levels during this process and HIF-2α levels are increased in
the epiphyseal growth plate where endochondral ossification takes place.84 That study
implicated HIF-2 as a regulator of endochondral ossification, but stating more
specifically its role in hypertrophic induction of chondrocytes in that process.
Hypertrophic chondrocytes have significant phenotypic changes along with
morphological changes that accompany them. As the onset of hypertrophy occurs,
chondrocytes began to greatly increase in size. The purpose of this change is to create a
space that the osteocytes can invade and create bone during endochondral ossification.
Phenotypically, there is a shift from the normally factors produced by chondrocytes to
factors that are not functional in this type of cartilage. The factors produced when
chondrocytes shift to hypertrophy are VEGF, collagen X, degrading proteins, such as
matrix metalloproteinases (MMPs), and different osteogenic related proteins, including
alkaline phosphatase (ALP), osteonectin, and osteocalcin, which are used in the creation
and maintenance of bone. VEGF is factor produced by cells responsible for the
recruitment of blood vessels to newly formed bone from pre-existing vessels. Collagen X
is a protein produced by hypertrophic chondrocytes and is a main component in the ECM
that replaces the main ECM component of healthy cartilage, collagen II. MMPs are
responsible for the degradation of ECM to allow creation of ECM with new components
or to remove damaged components. ALP is a factor produced by hypertrophic
chondrocytes and bone tissue and is involved with calcification. ALP and collagen X
have been studied and used to identify hypertrophic phenotypes in current literature.
Figure 1.2 shows the different proteins produced as chondrocytes move toward a
terminally differentiating state.
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As previously stated, the issue with cartilage tissue engineering currently is the frequent
onset of hypertrophy in engineered cartilage. The important conclusion to make in
understanding how to fix this process is that with the onset of hypertrophy comes new
protein production. As a result the tissue cannot survive in the joint due to poor
mechanical properties. More studies are required to determine how oxygen relates to the
progression of hypertrophy. Once it is clearly understood there will be much clearer ways
to solve the current problems seen with the creation of cartilage. Using conclusions
drawn from other studies that say HIF-2 is involved in the onset of hypertrophy, a study
to determine the effects on viability of ADSCs differentiated towards a chondrogenic
phenotype was formulated. It was hypothesized that HIF-2 inhibition during and after
chondrogenesis would result in a phenotype representative of native, functional cartilage
opposed to the hypertrophic phenotype seen in in vitro studies.

1.4 HYPOXIA INDUCIBLE FACTOR
O2 is a very important regulator of the group of vital transcription factors called
hypoxia-inducible factors (HIFs). As stated in the name, these factors become active in
states of reduced O2. HIFs are regulated through the fluctuations of O2 encountered
between physiological tissue and injured tissue. When hypoxia is encountered, there is a
reduction in the amount of available oxygen molecules present in and around the cell. As
a result, the α-subunits do not undergo proteosomal degradation via prolyl hydroxylation
and dimerize with the ever-present β-subunits. Upon creation of the heterodimer, binding
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Figure 1.2: Schematic showing different transcriptional and cases of the process of chondrocytes moving to a hypertrophic phenotype.
Also showing the main components produced by each phenotype.

to the hypoxia response elements (HRE) of target genes allows direct regulation of gene
activating pathways to allow the cell to survive in the toxic and stressful environment
created by the reduced oxygen concentration.85–87

Figure 1.3 shows the process of

transcriptional regulation under hypoxic conditions. The name hypoxia-inducible factor
is misleading by producing the thought that the factors stabilization only occurs under
hypoxia. Studies have also shown that HIFs stabilize under chemical regulation that
blocks the prolyl hydroxylation of the α-subunits and also under hyperoxic conditions,
oxygen concentrations higher than normal.88
HIFs have been implicated as potent regulators of a number of different pathways
that are involved in different tissues. Bone and cartilage are both different tissues that are
affected through the pathways set off by the HIF family both directly and indirectly. It
has been well studied that HIFs have a major part in angiogenesis, formation of
vasculature from preexisting vessels, through its regulation of vascular endothelial
growth factor (VEGF).89 HIF has also been shown to have an impact on bone formation
and repair, most likely though its role in angiogenesis, but it is difficult to discern
angiogenesis and osteogenesis because they are so closely related through development
and repair.90,91 Due to HIF-1s distinct role in angiogenesis it can be stated that bone
repair and, in turn, angiogenesis will be greatly hindered with the inhibition of HIF-1
activity, something that is not a desirable outcome for bone tissue engineering.
To understand how these pathways act, a thorough understanding of HIFs is
desired.

There are three different α-subunits, the unit degraded in the presence of

oxygen, known as HIF-1α, HIF-2α, and HIF-3α. Each α-subunit binds to a β-subunit,
which does not undergo degradation in response to oxygen abundance as seen with the α-
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Figure 1.3: Transcriptional Regulation of the HIF Pathway.

subunits. The complex stabilized under these conditions regulates a wide variety of
protein transcription. Studies have shown that they can act together or alone to affect
specific gene regulation, but there are still a lot unknown information about the HIFs.
Semenza was the first to discover HIF-1α almost two decades ago and because it was the
first to be discovered it also has the most known about it, HIF-2α is the next most studied
of the three, with HIF-3α having the most unknown.
As stated above, hypertrophy or the hypertrophic phenotype is more prevalent in
cells that are differentiated in vitro or re-differentiated and implanted into the injury site.
In vitro the cells tend to lack a "stop signal" to keep them from the onset of
hypertrophy.4 HIF function could play a role in this among other detrimental pathways
that occur in musculoskeletal tissues. HIF-1α and HIF-2α have both been debated as
having crucial roles in chondrogenesis and related to the onset of hypertrophy. One
example of the relationship between different HIF molecules is the conclusion drawn
from OA. It is known that elderly subjects are more predisposed to have issues related to
OA. Studies have shown that with increasing age and OA onset HIF-2 levels decrease,
whereas HIF-1 levels increase. Concluding that this reduction in HIF-2 activity is related
to the increase in HIF-1 expression, remarking that it is antagonist to HIF-1s degenerative
cartilage effects.92 Although this study indicated that HIF-2α reduction was related to the
onset of hypertrophy, many studies have found contradicting results. Based on the
differences seen in studies there is a need to determine the true roles played by the HIFs
regarding the onset of hypertrophy and OA. Saito et al. studied the role of HIF-2 during
skeletal growth and OA development. HIF-2 activity was linked to collagen type X (col
X), matrix metalloproteinase 13 (MMP-13), and VEGF due to their localization in the
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hypertrophic zone of samples studied. HIF-2 showed direct regulation of hypertrophic
indicators due to their reduction found in HIF-2 insufficient samples. Also in that study,
over 100 transcription factors allegedly involved in hypertrophy of chondrocytes were
analyzed from hypertrophic cartilage samples and HIF-2α was shown to have the highest
expression, labeling it to be highly linked to the onset of hypertrophy.72,78 Runx2, IHH,
PTH1R, MMP-3, and MMP-9 were also shown to be regulated by HIF-2α, which could
give mixed conclusions. Other studies have also shown that HIF-2α elevation is higher in
terminally differentiating chondrocytes , i.e. undergoing hypertrophy, and OA
cartilage.72,73,78,84,93 While some studies will support the argument that HIF-2α causes
OA, other studies have drawn conclusions that it actually acts to prevent it, as seen in the
study that showed that HIF-2 decreases with age which is when OA increases, but
without any other studies to back to support this conclusion seems baseless. Some
studies have also shown evidence that HIF-2α does help to suppress cartilage degradation
through down-regulation of proteins and enzymes which cause the breakdown to occur.94
A good question posed from these results is whether this role is played by HIF-2α or
hypoxia as a whole. These heterodimers regulate such a vast number of protein
production, therefore it is a given that some will be positive and others negative. One
negative result of HIF activation is the production of reactive oxygen species (ROS)
which is related to OA degradation. Although, the exact mechanisms in which HIF
causes ROS production is unknown, studies to determine a way to prevent it are required
to take steps toward OA prevention and repair.95
In conclusion, the current repair methods for musculoskeletal systems involve the
creation of multiple separate components that must not only integrate with the person it is
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implanted in, but it also requires the integration of the individual components to ensure
proper function. The current results of implantation of engineered constructs results in
low survival and engraftment. This is hypothesized to be a result of the traumatic change
from atmospheric culture to the deadly, hypoxic conditions encountered at the defect site.
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CHAPTER 2
Ischemic Preconditioning of ADSCs to Accelerate Bone Defect Repair
2.1 BRIEF INTRO TO IPC
Stem cells present a very promising technique for repairing organ defects. The
largest drawback with the use of stem cells for defect repair is the efficiency related to
low survival and engraftment of the transplanted cells at the target site. The reason for
the poor survival and engraftment is cellular apoptosis related to the dramatic shift from
atmospheric culture of the stem cells to the hypoxic environment encountered at the
defect site. IPC, for engineering any tissue, is a suggested strategy that could supply the
desired stimulus resulting in numerous responses including an increase in protein
expression related to survival pathways allowing protection from the hypoxic
environment. Another problem that IPC could solve, related to tissue engineering bone,
is that it could prime stem cells prior to differentiation into bone. Studies have shown
that osteogenesis is hindered under hypoxia. It is desired to have stem cells be implanted
into the defect site prior to differentiation to allow for vascularization of the newly
formed bone through angiogenesis. The idea here is that IPC would create a transition
period for the stem cells to begin to produce factors that will allow them to have a higher
capacity to differentiate into bone. The aim of this study is to show that IPC enhances
survival gene expression and to establish HIF-1s role in these survival pathways. Another
aim of this study is to establish the positive relationship between IPC and osteogenic
differentiation under hypoxic conditions to help enhance and accelerate bone formation.
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2.2 MATERIALS AND METHODS
2.2.1 ADSC CULTURE
Passage 1 (P1) ADSCs were purchased from a supplier (Invitrogen, Carlsbad,
CA). Cells were seeded and cultured in 75 cm2 culture flasks in humidified environments
of 5% CO2, and 95% air at 37°C (referred to as 20% O2 conditions). Cells were cultured
in MesenPro basal medium supplemented with MesenPro growth supplement, 1%
penicillin/streptomycin (Mediatech, Manassas, VA) and 2 mM L-glutamine (MP
Biomedicals, Irvine, CA). Once cultured cells reach between 80 and 90% confluence,
they were trypsinized (Corning Life Sciences, Manassas, VA) and a hemocytometer was
used to count the number of cells per milliliter to obtain the proper number of cells for
the study. Cells between P2 and P5 were used to ensure consistent cellular behavior, per
the manufacture's recommendation.

2.2.2 HIF-1 & 2 INHIBITION
To inhibit the activity of HIF-1 and HIF-2, a HIF-1 inhibitor (Calbiochem, USA)
and a HIF-2 inhibitor (Millipore, Billerica, MA) were used. The inhibitors selectively
block hypoxia-induced accumulation of cellular HIF-1α and HIF-2α, respectively. For
both 1% and 4% O2 samples, a concentration of 60 μM of the HIF-1 inhibitor and 10 μM
of the HIF-2 inhibitor were sufficient to reduce accumulation of HIF-1α and HIF-2α
levels below detection through western blotting. Cell viability tests showed no loss of
viability of ADSCs exposed to the inhibitors at their working concentrations.

25

2.2.3 ISCHEMIC PRECONDITIONING
Constant O2 levels of 1%, 2%, and 4% were maintained using nitrogen-purged,
programmable incubators. for the hypoxic studies (Napco Series 8000 WJ, Thermo
Electron). Cells were seeded into 6-well plates (100,000 cells/well) and placed in the
atmospheric oxygen incubator to allow for attachment over a 12 hour period. Following
the 12 hour attachment period, plates were moved to 1, 2 or 4% oxygen incubators for
ischemic exposure or left at atmospheric conditions. At each 24 hour time point
following, a new set of plates is moved from the atmospheric incubators to the hypoxic
incubators. This continues until 108 hours after initial seeding took place to create cells
that were exposed to 1, 2 or 4% O2 for 24, 48, 72 and 96 hours. To ensure exposure
hypoxic conditions were maintained for as much time as possible, all media, buffered salt
solutions, and fixatives used with the cells were allowed to pre-equilibrate in vented tubes
in the hypoxic incubator for 24 hours prior to use. Our lab has, in previous studies,
determined that is sufficient time to allow for equilibration of the dissolved oxygen
concentration.96 Also to limit exposure to higher O2 levels, media changes and imaging
procedures were kept under 10 minutes per day. It was determined in dissolved oxygen
studies that a 10 minute exposure to atmospheric conditions was small enough to allow
reestablishment of the oxygen level within 10 minutes of return to the incubator.

2.2.4

ANALYSIS

OF

ADSC

STEMNESS

AND

APOPTOSIS

BY

FLOW

CYTOMETRY
ADSCs were trypsinized and washed with a washing buffer. A hemocytometer
was then used to add 200,000 cells were added to each polystyrene flow cytometry tubes
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while on ice. Cells were stained with FITC conjugated CD44, PE conjugated CD105 and
a combination of both (BD Biosciences, San Diego, CA, USA).

DeadEndTM

Fluorometric TUNEL System was performed following the manufacturer's instructions to
assess apoptosis of ADSCs (Promega, USA). The Beckman Coulter-Cytomics FC 500
and CXP Analysis software were used to analyze the labeled cells.

2.2.5 PROTEIN EXTRACTION AND WESTERN BLOTTING
RIPA lysis buffer (Thermo Scientific, Rockland, IL) containing a protease and
phosphatase inhibitor (Thermo Scientific, Rockland, IL) was used to collect total cell
lysates from the samples. When added to the samples, they were stirred on ice for 10
minutes and sonicated for 15 minutes. The lysates were then centrifuged at 14000 rpm at
4°C for 15 min. Supernatants were collected and protein concentration was then
quantified with a Coomassie Plus Bradford Assay kit following the manufacturer's
instructions (Thermo Scientific, Rockford, IL).
Western blotting was then performed on the lysates by SDS-PAGE.
Approximately 50 μg of protein lysate was loaded per lane of 4-20% gradient gels.
Transfer to PVDF membranes (Millipore, Billerica, MA) followed after electrophoresis.
Following transfer to the membrane, a blocking phase followed. The membrane was first
incubated in 5% dry, milk, 1% bovine serum albumin (BSA) diluted in HBSS for 1 hour
at room temperature. The membrane was then washed for 15 minutes in a wash solution
(0.1% Tween-20, 0.1% dry milk, 0.1% BSA in HBSS). Next, the membrane was
incubated with rabbit anti-HIF-1α antibody (1:1000)(Santa Cruz Biotechnology, Santa
Cruz, CA), rabbit-anti-pAKT (1:1000), rabbit anti-bcl-2 antibody (1:1000), rabbit anti-
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Bax antibody (1:1000), rabbit anti-active Caspase-3 antibody (1:1000), rabbit antiOsteonectin antibody (1:1000), rabbit anti-Osteopontin antibody (OPN)(1:1000), or
rabbit anti-β-actin antibody (1:1000)(Santa Cruz Biotechnology, Santa Cruz, CA)
overnight at 4°C. The next step involved 3 washes of 15 minutes each in the previously
mentioned wash. Then membranes were incubated in a secondary antibody, peroxidaseconjugated, goat, anti-rabbit IgG (1:5000)(Rockland Immunochemicals, Gilbertsville,
PA) for 2 hours on an orbital shaker for 2 hours. Following incubation in the secondary
antibody, membranes were washed 3 times for 15 minutes in a new wash (0.1% Tween20 in HBSS). Prior to imaging, the membranes were exposed to a chemilluminescence
reagent, SuperSignal West Pico Substrate (Thermo Scientific, Rockford, IL) for 5
minutes. ChemiDocTM XRS+ System with Image LabTM image acquisition and analysis
software was used to for band detection (Bio-Rad, Hercules, CA). Image J program was
used for densitometry analysis. For densitometry analysis, the expression of all proteins
was normalized to β-actin to account for % IOD (intensity optical density). All incubation
steps took place on an orbital shaker set to continuously rotate at 200 rpm. The statistics
shown represent results from three independent studies.

2.2.6 OSTEOGENIC DIFFERENTIATION
Induction of osteogenic differentiation was through culture in StemPro®
Osteocyte/Chondrocyte Differentiation Basal Medium and StemPro® Osteogenesis
supplement (Invitrogen, USA). Cells were monitored over a 4 week period at 2% O2,
exchanging the used medium for fresh preconditioned media every 3 days. After
completing the initial IPC studies it was determined based on optimal survival, the Bcl-
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2/Bax ratio, that the best results were in the 72 hour IPC condition. Therefore IPC
performed prior to osteogenic differentiation was performed for 72 hours at all O2
concentrations. All preconditioned cells and one set of cells cultured in 20% O2 were
differentiated in 2% O2.

2.2.7 ALP ACTIVITY AND DNA QUANTIFICATION
Media samples were taken on days 7, 14, 21 and 28 to analyze for ALP activity.
An ALP colorimetric assay kit (Abcam, USA) with p-nitrophenyl phosphate as the
substrate was used to determine the activity. ALP activity was normalized to cellular
DNA content using a PicoGreen dsDNA quantitation kit (Molecular Probes, USA)
following the manufacturer's instructions.

2.2.8 QUANTIFICATION OF MINERALIZATION VIA ALIZARIN RED STAINING
Samples were collected on days 14 and 28 to quantify mineral deposition using an
Alizarin Red staining procedure. Cells were first rinsed with calcium and phosphate-free
HBSS, and fixed with 70% ethanol for 1 hour on ice. Following another brief wash with
HBSS, cells were stained for 20 minutes with 40 mM Alizarin Red staining solution (pH
4.2) at room temperature. Cells were then rinsed with 2 exchanges for 15 minutes in
HBSS to reduce nonspecific staining. Next, a 10% acetic acid solution was added to the
samples for 30 minutes. Samples were collected by scraping and were then headed at
80°C for 10 minutes. Extracts were centrifuged at 8000 rpm for 20 minutes and
quantified using a microplate reader (Biotek, USA) at 570 nm. Calcium concentrations
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were calculated from the standard curved generated using a serial dilution of a calcium
standard solutions and then values were normalized to DNA contents.

2.2.9 STATISTICAL ANALYSIS
Statistical analysis was performed with Microsoft Excel and Graphpad Prism 4.01
(GraphPad Software Inc., San Diego, CA). Experimental results are expressed as the
mean ± standard deviation and were analyzed by two-way ANOVA for comparisons and
p-values <0.05 were defined to be statistically significant.

2.3 RESULTS
2.3.1 FLOW CYTOMETRY FOR STEMNESS
Flow cytometry revealed that the percentage of ADSC population after
preconditioning for the longest period of time (96 hours) in 1%, 2%, 4% and 20% O2
were 99. 5±0.05 %, 99% ±1%, 98.8% and 99% ±1%, respectively, as shown in Appendix
1.

2.3.2 IPC PROTEIN EXPRESSION
In the 1% O2 preconditioning set up, the pAKT expression was 7.61±0.43,
8.52±0.61, 12.16±0.56 and 14.13±0.71 at 24, 48, 72 and 96 hours respectively. The
preconditioning set up under 2% O2 expressed pAKT as 6.82±0.32, 10.24.52±0.73,
12.37±0.36 and 12.56±0.66 at 24, 48, 72 and 96 hours respectively.
Active caspase-3 expression is as follows. In the 1% O2 preconditioning set up
the expression was 0.91±0.52, 12.14±0.81, 13.43±0.76 and 18.24±0.92 at 24, 48, 72 and
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96 hours respectively. In the 2% O2 preconditioning set up was 0.83±0.31, 0.85±0.24,
13.43±0.69 and 13.53±0.82 at 24, 48, 72 and 96 hours respectively.

Protein expression of Bcl-2 and Bax is expressed as a ratio of Bcl-2 to Bax. This
is a standard ratio in literature looking at the enhancing cell survival. Bcl-2 is an antiapoptotic protein, while Bax is an apoptotic protein. Therefore this ratio is viewed as a
representation of anti-apoptotic proteins to pro-apoptotic proteins to determine whether
there has been an increase of survival. In 1% O2the Bcl-2/Bax ratio expression was
1.34±0.31, 3.15±0.36, 3.41±0.46 and 3.53±0.23 at 24, 48, 72 and 96 hours respectively.
In 2% O2 condition, the Bcl-2/Bax ratio expression was 2.62±0.43, 3.23±0.27, 4.36±0.21
and 4.16±0.35 at 24, 48, 72 and 96 hours respectively.
In 1% O2 preconditioning set up the HIF-1α expression was 8.92±2.51,
9.12±1.23, 10.52±1.34 and 14.12±1.46 at 24, 48, 72 and 96 hours respectively. In 2%
oxygen condition, the HIF-1α expression was 7.31±1.31, 8.76±0.83, 9.85±1.25 and
14.9±1.37 at 24, 48, 72 and 96 hours respectively.
All protein expression is represented in %IOD fold difference against the samples
in 20% oxygen. Figure 2.1 shows the collected results for all of the protein expression
data and appendix 2 shows a representative image of the gel.

2.3.3 EFFECTS OF IPC ON OSTEOGENIC DIFFERENTIATION
ALP activity of samples taken on day 28 in 2% O2 after no preconditioning, 1%
O2, 2% O2 and 4% O2 was 19.31± 1.23, 24.21± 4.11, 28.21±1.9 and 29.32± 3.14
μmol/ml/min/mg DNA, respectively. Quantification of mineralization under the same
conditions as above was 36.87± 2.76, 42.81± 2.36, 39.72±3.91 and 39.22± 4.12 mg
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mineral/mg DNA on day 28, respectively. Protein expression for the osteogenic markers
osteonectin (ON) and OPN were taken on day 28.
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Figure 2.1: Quantification of the Expression of Apoptotic Proteins in 1%, 2% and 4% O2 Environments through all four IPC
time points.

ON expression of samples taken on day 28 from 2% O2 after no preconditioning, 1% O2,
2% O2 and 4% O2 was 2.61±0.21, 3.56±0.53, 3.81±0.34 and 3.96±0.57 %IOD fold
difference was observed. OPN expression of samples taken on day 28 in 2% O2 after no
preconditioning, 1% O2, 2% O2 and 4% O2 was2.11±0.34, 3.73±0.62, 3.42±0.82 and
3.53±0.31 %IOD fold difference was observed. All of these results can be seen portrayed
in figure 2.2.

2.3.3 EFFECTS OF IPC ON OSTEOGENIC DIFFERENTIATION
ALP activity of samples taken on day 28 in 2% O2 after no preconditioning, 1%
O2, 2% O2 and 4% O2 was 19.31± 1.23, 24.21± 4.11, 28.21±1.9 and 29.32± 3.14
μmol/ml/min/mg DNA, respectively. Quantification of mineralization under the same
conditions as above was 36.87± 2.76, 42.81± 2.36, 39.72±3.91 and 39.22± 4.12 mg
mineral/mg DNA on day 28, respectively. Protein expression for the osteogenic markers
osteonectin (ON) and OPN were taken on day 28.
ON expression of samples taken on day 28 from 2% O2 after no preconditioning, 1% O2,
2% O2 and 4% O2 was 2.61±0.21, 3.56±0.53, 3.81±0.34 and 3.96±0.57 %IOD fold
difference was observed. OPN expression of samples taken on day 28 in 2% O2 after no
preconditioning, 1% O2, 2% O2 and 4% O2 was2.11±0.34, 3.73±0.62, 3.42±0.82 and
3.53±0.31 %IOD fold difference was observed. All of these results can be seen portrayed
in figure 2.2.
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2.4 DISCUSSION
Analysis of the results showed that the anti-apoptotic and pro-apoptotic markers
were regulated by IPC in both a time and O2 dependent manner. It was noticed that
ADCSs that experienced IPC in the 1% and 2% O2 concentrations expressed higher
levels of apoptotic markers than those expressed from ADSCs that underwent IPC in 4%
O2. It was also shown that with the use of the HIF-1 inhibitor, the Bcl-2/Bax ratio was
reduced with no effect on the levels of pAKT and active caspase-3. Figure 2.3 shows the
results of HIF-1 inhibition on the Bcl-2/Bax ratio.

With regards to osteogenic

differentiation, cells that underwent any form of IPC exhibited enhanced osteogenic
marker expression compared to cells that did not experience any form of IPC.
Survival of transplanted cells is a known problem in the field of tissue
engineering. Many strategies have been examined in attempts to promote survival and
engraftment at the injury site. Some of these strategies are, but not limited to, knocking
down pro-apoptotic genes, genetic manipulation through anti-apoptotic protein and gene
over expression, and infusion of neurotrophic factors continuously.97–100 Although these
studies have proposed great strategies for increasing survival, limitations have become
more apparent, such as clinically impracticality, concerns with the efficacy of targeting a
single gene or signaling cascade, and the safety issues connected with permanent gene
modification. Compared to the previously listed proposed solutions for survival and
engraftment at defect sites, IPC has produced some promising results. In order for stem
cells to surmount stresses encountered at the injury site, optimization of IPC conditions is
of extreme importance for in vitro activation of ADCSs.
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Figure 2.2: Effect of IPC on Osteogenic Differentiation of ADSCs.
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Figure 2.3: Effect of HIF-1 Inhibition on Survival Criteria Proteins to Gauge HIF-1's Role in Survival.
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Chapter 3
Inhibition of HIF-2α during Chondrogenesis for Cell Survival Leading to Prevention
Hypertrophy
3.1 BRIEF INTRO TO HIF-2Α'S ROLE IN HYPERTROPHY
Hypertrophy is a step in the formation of bone, known as endochondral
ossification, where chondrocytes swell to create a space for osteoblasts to invade and
begin bone formation. Studies have shown that levels of HIF-2α are decreased in the
hypertrophic zone of ossifying bone during development.78 Saito et al. also showed that
through HIF-2α inhibition there was a reduction in cartilage degradation and osteophyte
formation, but these studies were oriented more towards development. To aid in the
formation of implantable tissue constructs, in vitro studies of HIF-2α's effects on
apoptosis during chondrogenesis are required. The development of a method to prevent
hypertrophy, or apoptosis, during in vitro chondrogenesis would provide more insight to
regeneration of cartilage for cartilage defect or OA cartilage repair.

This study aims to

determine the effects of a HIF-2 inhibitor at different stages of in vitro chondrogenesis
(middle and end) on apoptosis and hypertrophic marker expression ADSCs in 3D culture.

3.2 MATERIALS AND METHODS
3.2.1 ADSC CULTURE
Passage 1 (P1) ADSCs were purchased from a supplier (Invitrogen, Carlsbad,
CA). Cells were seeded and cultured in 75 cm2 culture flasks in humidified environments
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of 5% CO2, and 95% air at 37°C (referred to as 20% O2 conditions). Cells were cultured
in MesenPro basal medium supplemented with MesenPro growth supplement, 1%
penicillin/streptomycin (Mediatech, Manassas, VA) and 2 mM L-glutamine (MP
Biomedicals, Irvine, CA). Once cultured cells reach between 80 and 90% confluence,
they were trypsinized (Corning Life Sciences, Manassas, VA) and a hemocytometer was
used to count the number of cells per milliliter to obtain the proper number of cells for
the study. Cells between P2 and P5 were used to ensure consistent cellular behavior, per
the manufacture's recommendation.

3.2.2 ADSC SPHEROID FORMATION
A similar approach to ADSC spheroid formation was performed previously and
described in a preceding paper.101

Once cells reached 80-90% confluence trypsin

(Corning Life Sciences, Manassas, VA) was used to detach them from the flask. A
hemocytometer was used after resuspension in MesenPro medium (Invitrogen, Carlsbad,
CA) to reach a cell density of 1,000,000 cells/mL. Media containing either 20,000 (20k),
60,000 (60k), or 200,000 (200k) cells was added to 0.8 mL, siliconized screw-cap
microcentrifuge tubes (VWR, Radnor, PA) and spun at 500 rcf for 2 minutes. Screw caps
were then loosened to allow gas transfer and the tubes were placed in an incubator set at
20% O2 overnight.

After 24 hours for initial formation of 3D spheroids through

spontaneous self-assembly, wide-mouth tips were used with a micropipette, to prevent
shearing, to carefully collect the pellets and use them for the study.
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3.2.3 PELLET SIZE EXPERIMENTS
To determine the pellet size to use for the HIF-2 inhibition study over an extended
period of time, apoptosis studies were set up. Following cohesion of pellets of sizes: 20k,
60k, and 200k, the pellets were all placed in a 2% O2 incubator for 7 days. Media was
exchanged each day, adding 200 μL of preconditioned ADSC media. On day 7 pellets
were placed in zinc formalin (VWR, Radnor, PA) for 24 hours to fix them for paraffin
embedding.

3.2.4 EFFECTS OF HIF-2Α ON ADSC VEGF PRODUCTION
Spheroids were formed and allowed 24 hours for cohesion. Pellets were then
divided evenly into six different categories based on pellet size and +/- 10 μM HIF-2α
inhibitor as follows: 20k - inhibitor, 20k + inhibitor, 60k - inhibitor, 60k + inhibitor, 200k
- inhibitor, and 200k + inhibitor. Media was collected around the same time each day for
8 days and frozen. Following media collection from the pellets, a VEGF ELISA kit was
performed, per the manufacturer's instructions (Invitrogen, Carlsbad, CA).

3.2.5 HIF-2 INHIBITION STUDY
Spheroids were formed and allowed 24 hours for cohesion. Pellets were
distributed evenly 9mm petri dishes (VWR, Radnor, PA) labeling each with one of six
different conditions as follows: 20k and 200k pellets with no addition of HIF-2 inhibitor
(called no), 20k and 200k pellets with the addition of HIF-2 inhibitor at the midpoint of
induced chondrogenesis (day 14, called early),

and 20k and 200k pellets with the

addition of HIF-2 inhibitor at the initiation of hypertrophy (day 28, called late). Upon
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distribution to the petri dishes, 3 mL of preconditioned media is added to each petri dish
and they are placed into the 2% O2 incubator. Every 3 days the media approximately
80% of the media is removed using wide mouthed pipette tips to reduce chances of
tearing the pellets. Chondrogenic media (Invitrogen, Carlsbad, CA) is added to the
pellets through day 28. After day 28, hypertrophic media, based on a formula from
another study74, is added to the pellets through day 49. After day 14, only the groups
labeled early received 10 μM of HIF-2 inhibitor to the chondrogenic media from this day
forward. After day 28, the groups labeled late received inhibitor for the rest of the study.
Therefore, after day 28 the only groups without any addition of HIF-2 inhibitor in the
media was the group labeled "no". Media samples were collected on days 7, 14, 21, 28,
35, 42, and 49 for alkaline phosphatase analysis. On day 49 the pellets were placed in
zinc formalin (VWR, Radnor, PA) for 24 hours to fix them for paraffin embedding.

3.2.6 ALP ANALYSIS
ALP samples collected on days 7, 14, 21, 28, 35, 42, and 49, were analyzed using
an ALP colorimetric assay (Abcam, Cambridge, MA), per the manufacturer's
instructions.
3.2.7 PARAFFIN EMBEDDING
Following fixation the pellet goes through an embedding preparation process,
including dehydration, clearing, and infiltration. This process includes the following
steps: was in running water, submerge in 80% alcohol, then in 95% alcohol for 3 changes
for 15 min each, 3 changes in absolute alcohol for 15 min each, submerge in 50/50
absolute alcohol and xylene for 15 min, 2 changes of xylene for 15 min each, 3 changes
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of paraffin for 15 min each, and finally in paraffin under vacuum for 15 min. After the
final step embedding may take place. After embedding in paraffin the block must be cut
with beveled edges for ease of cutting on the tome.

3.2.8 PELLET SECTIONING
Pellets were cut using a microtome (Reichert-Jung 2030) at a thickness of 5 μm.
The newly cut section is then laid in a warm-water bath (Triangle Biomedia Sciences) to
release wrinkles prior to placement of glass microscope slides (Superfrost Plus).

3.2.9 HEMATOXYLIN AND EOSIN STAINING
Following deparaffinization and hydration of slides in distilled water, the slides
go through the following progression of submersion: xylene for 3 min, xylene for 3 min,
100% alcohol, 100% alcohol, 95% alcohol, 80% alcohol, water wash, hematoxylin for 7
min, water wash, acid alcohol, water wash, ammonia water, water wash, eosin for 2 min,
95% alcohol, 95% alcohol, 95% alcohol, 100% alcohol, 100% alcohol, then three dips in
xylene. After the progression is completed the slides should be cover slipped.

3.2.10 SAFRANIN O STAINING
Following deparaffinization and rehydration to water, the slides are stained with
Weigert's iron hematoxylin working solution for 7 minutes. Next running tap water is
used to wash the slide for 10 minutes and a fast green stain solution (0.1g fast green in 1
L of water) is applied for 3 minutes. A quick rinse of approximately 10 seconds is
performed, following the fast green stain, with a 1 % acetic acid solution. Safranin O
42

solution (1g of safranin O and 100 mL of water) is then added to stain the slide for 5
minutes, followed by dehydration and clearing with 95% ethyl alcohol, 100% ethyl
alcohol, and xylene through 2 changes of 2 minutes each. Following rinsing the slides
were mounted with a coverslip for microscopy.

3.2.11 STATISTICAL ANALYSIS
Statistical analysis was performed with Microsoft Excel and Graphpad Prism 4.01
(GraphPad Software Inc., San Diego, CA). Experimental results are expressed as the
mean ± standard deviation and were analyzed by two-way ANOVA for comparisons and
p-values <0.05 were defined to be statistically significant.

3.3 Results
3.3.1 EFFECTS OF HIF-2 INHIBITION ON VEGF PRODUCTION IN ADSCS
The analysis of VEGF production of ADSCs was measured using a VEGF ELISA
kit. Results indicated that there was no significant difference between VEGF production
of cells with and without the addition of HIF-2 inhibition. It is worthy to note also that
after the initial release of VEGF, the amount present after every day later reduces. Figure
3.1 shows the results of the VEGF ELISA to determine if HIF-2 has any effect on the
production of VEGF in ADSCs.

3.3.2 EFFECT OF HIF-2 INHIBITION ON ALP PRODUCTION
Results of the colorimetric ALP assay used to asses ALP levels during the HIF-2
inhibition study showed that ALP levels were similar for each group. Typically, ALP
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levels were high in pellets that received late induction of HIF-2 inhibitor, but the
difference was deemed insignificant. Results of the ALP analysis are shown in Figure
3.2.

3.3.3 HEMATOXYLIN AND EOSIN STAINING
H&E staining was performed on pellets of 20k and 200k after 7 days of hypoxic
culture in ADSC medium and at day 49 following culture in hypertrophic and
chondrogenic medium.

3.3.3.1 7-DAY HYPOXIC CULTURE
Viewing sections of 200k pellets after 7 days of hypoxic culture, as the cuts
became closer to the center of the pellet significantly more necrosis occurred. Viewing 3
sections of the same pellet, at a magnification of 10x, each approximately 120 μm apart,
the final section being the most central representation, necrosis increased from
approximately 25% to 40% to 65%, respectively.

Three 20k pellets were viewed

approximately 20 μm apart each, the final being the central most cut. When viewing the
20k pellets at 10x magnification, there was very little, if any, visible necrosis with the
possibility of >5% in the most central cut. Figure 3.3 shows the visual representation of
each of these pellet sections.
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Figure 3.1: VEGF production in ADSCs with and without HIF-2 inhibitor.
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Figure 3.2: ALP activity with different induction points of the HIF-2 inhibitor.
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47
Figure 3.3: Pellet sections of a 200k pellet (A, B and C) and a 20k pellet (D, E and F) after 7 days of hypoxic culture. Red circles
indicate areas of necrosis visible by the darker purple stain and areas of cells pulling away from each other. Legend shows the depth at
which each section was approximately cut at.

3.3.3.2 49-DAY STUDY OF ADSCS UNDERGOING CHONDROGENIC AND
HYPERTROPHIC DIFFERENTIATION
H&E staining was performed on 200k pellets that were exposed to the HIF-2
inhibitor and pellets that were not exposed to HIF-2. Figure 3.4 shows the effect of the
HIF-2 inhibitor on apoptosis. The 200k pellet that was not exposed to the HIF-2 inhibitor
had a much larger degree of necrosis including loss of the original size of the pellet
compared to 200k pellet exposed to the HIF-2 inhibitor.

3.3.4 SAFRANIN O STAINING
Safranin O staining, with a counter stain of hematoxylin, of 20k and 200k pellets
exposed to no HIF-2 inhibitor, exposure to HIF-2 inhibitor after 14 days of chondrogenic
induction (early), and exposure to HIF-2 inhibitor after 28 days of chondrogenic
induction (late). There is significantly more necrosis in 200k pellets compared to 20k
pellets based on the hematoxylin counter stain.

It is visually evident that pellets

introduced to the HIF-2 inhibitor earlier, had more collagen shown by the amount of
safranin O stain picked up, as shown in figure 3.5.

3.4 DISCUSSION
It is well known that HIF-1 has a direct role in the regulation of VEGF secretion
of stem cells.51,78,101,102 HIF-2's role in VEGF production, on the other hand, is much less
documented. Here it was shown that HIF-2 had no visible regulation on the production
of VEGF over a known period where VEGF secretion is its highest. Therefore, if HIF-2
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49
Figure 3.4: H&E sections of 200k pellets after 49 days of chondrogenic and hypertrophic differentiation. A) Shows a 200k pellet
differentiated under HIF-2 inhibition compared to B) Showing a 200k pellet section differentiated without the HIF-2 inhibitor.
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Figure 3.5: Safranin O stained sections of 200k (A and B) and 20k (C, D and E) pellets. Pellets A and C were cultured without any
HIF-2 induction at all, while B, D and E was differentiated with HIF-2 inhibition, D had inhibition after day 14 and B, E had
inhibition after day 28. There is significantly more visible necrosis in 200k pellets compared to 20k pellets, but comparing pellets that
had HIF-2 inhibition it is visible that the earlier the inhibitor was added, the less necrosis occurred.

inhibition is found to have a crucial and definite role in the hypertrophy and cell death,
then its inhibition would not warrant the addition of supplemental VEGF.
As ALP activity was measured over the 7 week span, there was no significant
difference in the values received between the different groups. HIF-2 has been linked in
literature to a role in ALP regulation, a known hypertrophic marker, so it would be odd
that through inhibition of HIF-2 there was not a visible difference.51,56,71,74,78 One possible
explanation this could be the cell death that was seen in the safranin O and H&E staining.
As shown by the qualitative results obtained through safranin O and H&E
staining, there is a clear advantage in the use of HIF-2 inhibitor even when producing
larger pellets. The initial pellet size study, for determining the size of pellet to use for the
longer study, revealed similar results to similar studies produced in our lab.101 Although
it was determined that larger pellets are more difficult to use due to issues of necrosis, a
set of 200k pellets was performed during the long study to determine if HIF-2 inhibition
had positive effects on sustaining cell viability in pellet culture. Not only was this idea
confirmed in 200k pellets, but it was also evident that in 20k pellets that were exposed to
the HIF-2 inhibitor earlier in the study. This was also similarly seen regarding collagen
and GAG content through safranin O staining. One explanation for why there was more
collagen in the early inhibitor pellet sets is that there is not as much apoptosis and
necrosis present therefore more collagen can be produced. From this study it is learned
that there is a possible link between HIF-2 inhibition and survival in 3D ADSC pellets
during chondrogenic differentiation no matter the size of the pellet.
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APPENDIX A – ISCHEMIC PRECONDITIONING
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Figure A.1: Flow cytometry of ADSCs after 96 hours of IPC at the three O2 concentrations of interest.

61

Figure A.2: Western blots showing apoptotic protein expression in the three O2 concentrations of question at the
different IPC time points.

